Unlocking the Potential of C1orf226: A drug Target and Biomarker

Target Name: C1orf226

NCBI ID: G400793

C1orf226

Unlocking the Potential of C1orf226: A drug Target and Biomarker

C1orf226 is a protein that is expressed in various tissues of the human body. Its unique structure and function make it an attractive target for drug development. This protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will explore the potential of C1orf226 as a drug target and biomarker.

C1orf226: A protein for drug development

C1orf226 is a transmembrane protein that is expressed in various tissues of the human body. It plays a critical role in cell signaling, inflammation, and tissue repair. One of its unique features is its ability to interact with multiple signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. This makes C1orf226 an attractive target for drug development due to its broad range of potential drug targets.

C1orf226 has been identified as a potential drug target for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, studies have shown that inhibiting C1orf226 can lead to therapeutic effects in cancer cells. This is because C1orf226 is involved in cell signaling pathways that promote cancer cell growth and survival. Additionally, C1orf226 has been shown to be involved in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. By targeting C1orf226, researchers may be able to develop new treatments for these debilitating diseases.

C1orf226 as a biomarker

In addition to its potential as a drug target, C1orf226 has also been identified as a potential biomarker for various diseases. Its unique structure and function make it an attractive target for diagnostic tools, such as mass spectrometry-based assays and affinity purification chromatography.

One of the potential benefits of using C1orf226 as a biomarker is its ability to diagnose diseases at an early stage. For example, C1orf226 has been shown to be expressed in various tissues of the human body, including the brain, spleen, and pancreas. This makes it an potential biomarker for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, C1orf226 has been shown to be involved in cancer, including ovarian cancer, and may be a potential biomarker for this disease.

Another advantage of C1orf226 as a biomarker is its stability and expression in different tissues. This makes it an potential biomarker that can be used to diagnose diseases at different stages, such as early and late stages. Additionally, C1orf226 has been shown to be expressed in various biological samples, including blood, urine, and tissue samples, making it an potential biomarker for a wide range of diseases.

Conclusion

In conclusion, C1orf226 is a protein that has the potential to be a drug target and biomarker for various diseases. Its unique structure and function make it an attractive target for drug development, and its ability to interact with multiple signaling pathways makes it an potential biomarker for a wide range of diseases. Further research is needed to fully understand the potential of C1orf226 as a drug target and biomarker.

Protein Name: Chromosome 1 Open Reading Frame 226

The "C1orf226 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1orf226 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets